BridgeMD
New treatment option for Stroke
Official title Addiction & Stroke
ClinicalTrials.gov ID: NCT06187025
What this study is testing
- What it's testing
- Modifiable stroke risk-factors, which include poor lifestyle habits, account for 90 % of the risk of stroke. Disability Adjusted Life Years (DALYs) related to cerebrovascular disorders rely on three main factors, including the severity of stroke-related symptoms, the occurrence of stroke complications, and stroke recurrences.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Male or female
- At least 18 years of age and younger than 80 years;
- Recent (≤ 15 days) clinically symptomatic ischemic or hemorrhagic stroke documented through brain imaging (CT or MRI) or a Transient Ischemic Attack...
- Returning to the Bordeaux Hospital neurovascular unit for the standard care 3-months post-stroke follow-up visit;
- National Institute Health Stroke Scale (NIHSS) \< 15;
You likely can't join if
- Subarachnoid hemorrhage; Dementia syndrome or other neurologic disorder;
- Severe aphasia (NIHSS item 9 ≥ 2) and/or Severe visual impairment interfering with the completion of evaluations;
- Severely impaired physical and/or mental health that, according to the neurologist, may affect the participant's capacity to participate in the study;
- Pregnancy or breastfeeding;
- Inability to read French;
- Individuals under legal protection or unable to personally express their consent
See the full eligibility criteria
- Male or female
- At least 18 years of age and younger than 80 years;
- Recent (≤ 15 days) clinically symptomatic ischemic or hemorrhagic stroke documented through brain imaging (CT or MRI) or a Transient Ischemic Attack with an ABCD2 score ≥ 4;
- Returning to the Bordeaux Hospital neurovascular unit for the standard care 3-months post-stroke follow-up visit;
- National Institute Health Stroke Scale (NIHSS) \< 15;
- modified Rankin scale ≤ 4;
- No severe cognitive impairment as defined by the neurologist;
- Written informed consent by the patient;
- Coverage by the French National Health Insurance. For the feasibility study assessing the acceptability of the eHealth device to optimize stroke secondary prevention, additional will be the ability to use a smartphone...
- Subarachnoid hemorrhage; Dementia syndrome or other neurologic disorder;
- Severe aphasia (NIHSS item 9 ≥ 2) and/or Severe visual impairment interfering with the completion of evaluations;
- Severely impaired physical and/or mental health that, according to the neurologist, may affect the participant's capacity to participate in the study;
- Pregnancy or breastfeeding;
- Inability to read French;
- Individuals under legal protection or unable to personally express their consent
- Participation in another protocol modifying the patient's follow-up status
The study team makes the final eligibility decision.
Where it's taking place
- Bordeaux, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bordeaux, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.